Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT03707509 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

263

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Placebos
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Jiangsu HengRui Medicine Co., Ltd.